OTC Medicines

Browse OTC Medicines Content

CHPA appreciates the opportunity to provide feedback on the notice requesting comments on the Inactive Ingredient Database (IID). Responses to each of the questions listed by FDA in the March 22, 2022 notice are provided.

Jun 21, 2022

Industry executives from Europe and beyond gathered June 7-8, in Madrid, Spain, for the annual meeting of the Association of the European Self-Care Industry (AESGP), its first annual meeting since 2019. Under the theme “supporting innovation in self-care during times of uncertainty,” speakers focused on the European context of environmental sustainability, trends shaping the future of the consumer healthcare business, and the outlook for changes to the EU’s pharmaceutical framework, among other topics.

Jun 9, 2022

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

Jun 8, 2022

Awareness of acetaminophen safe use and the risks of using too much remains high, indicating that ongoing education is critical to continued progress.

Jun 6, 2022

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

May 25, 2022

CHPA’s President & CEO, Scott Melville, released a statement in response to the FDA Safety and Landmark Advancement (FDASLA) Act of 2022.

May 18, 2022

CHPA has issued a statement in response to a recent, observational NSAID study published in the journal Science Translational Medicine.

May 17, 2022

In late 2021, the Global Self-Care Federation launched the Charter for Environmentally Sustainable Self-Care, the first industry-wide climate action resolution issued by the consumer health sector.

Apr 25, 2022

Filter Results